Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The COVID-19 International Modelling Consortium (CoMo Consortium) was created by researchers at the University of Oxford and Cornell University, is partnering with infectious disease modellers and public health experts from over 40 countries in Africa, Asia and America. The CoMo Consortium uses a participatory approach to provide decision-making support to policymakers, using evidence from epidemiological and economic models adapted to each country’s context.

The COVID-19 International Modelling Consortium (CoMo Consortium) - image of he world highlighting countries with CoMo members, its logo and the text CoMo Consortium

COVID-19 is continuing to spread across the world at a rapid rate. By 30 April 2020, the pandemic had affected at least 185 countries/regions, with more than 4 million confirmed cases and in excess of 200,000 deaths globally. The pandemic has presented a myriad of challenges for health care systems around the world, including pressures on health care staff, general hospital beds, intensive care capacity and specialized equipment. In addition to the health effects of the disease, lockdown measures to contain the disease have placed a significant economic burden on countries and communities. Policymakers must balance curtailing the negative health effects of the pandemic against minimizing the economic impact on societies, calibrating these decisions for the epidemiological, social, cultural and infrastructure context of an individual country. There is currently no treatment or vaccine for COVID-19, so countries that choose to try to interrupt its spread must rely on non-pharmaceutical interventions (NPIs); these NPIs fall into various categories of behaviour change, including self-isolation for symptomatic individuals, increased hand hygiene, and physical distancing in social settings.

The COVID-19 International Modelling Consortium (CoMo Consortium) was created by researchers at the University of Oxford together with academic colleagues at Cornell University and is partnering with infectious disease modellers and other public health experts from more than 40 countries across Africa, Asia, and South and North America. The CoMo Consortium uses a participatory approach to provide decision-making support to policymakers, using evidence from epidemiological and economic models adapted to each country’s context.

The CoMo Consortium has developed an age-structured, compartmental SEIR (susceptible-exposed-infectious-recovered) model to estimate the trajectory of COVID-19 based on different scenarios and to assess the potential impact of the various NPIs, as well as treatments and vaccines, when they become available. A user-friendly, web-based interface enables training on and use of the model by member modelling groups, while dashboards and visualization tools allow policymakers to see the predicted impacts of different NPIs in real time. The CoMo Consortium comprises several working groups, with each group playing a specific role, as outlined below.

CoMo Consortium working groups

  • Policy support. Facilitating a direct link between the modellers (from multiple countries) involved in developing the models and interpreting their outputs, the in-country experts and the policymakers in each country.
  • Model development. Writing, coding, debugging and updating the primary model structure.
  • Interface development. Creating a web-based interface that enables non-modellers to run the models, based on their local parameters.
  • Economic modelling. Conducting modelling to assess the economic costs and impacts arising from an intervention or a suite of interventions.
  • Evidence synthesis. Combining scientific evidence relating to the COVID-19 pandemic with model projections, economics and financing to create evidence-based policy briefs.
  • Outreach and communications. Engaging both in-country experts and policymakers who are seeking additional modelling support to deal with their specific COVID-19 situation.

CoMo Consortium model outputs

The predictions of the model can enable policymakers to make data-based decisions to inform their public health responses, such as:

  • The impact of the various mitigation strategies on virus transmission, mechanisms for ‘flattening he epidemic curve’, lockdown release strategies, and deciding which interventions will be most effective in their specific context.
  • The comparative demand for general hospital beds and ICU beds under different intervention strategies.
  • The quantity of tests, personal protective equipment, ventilators and other supportive tools needed for the diagnosis and treatment of patients with COVID-19, and the costs of the equipment needed.

The CoMo Consortium model is currently being used around the world to facilitate policy discussions and shape intervention strategies. It is also being modified for local purposes by the in-country teams and being used as a comparator with existing in-country models.

- Thank you Rima Shretta for this text and images


What is mathematical modeling and how can it help control the COVID-19 pandemic?
Video produced by
WHO Eastern Mediterranean Region

An update of this story is available on the Oxford Tropical Medicine website

Similar stories

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Lack of evidence is key barrier to using portable devices to detect poor quality medicines

A series of papers which reviewed portable devices to detect poor quality medicines has concluded major gaps in scientific evidence remain a key barrier for regulators to implement surveillance systems using such devices.

RECOVERY Trial paper on dexamethasone wins BMJ’s 2021 UK Research Paper of the Year Award

A RECOVERY Collaborative Group paper has been announced as the 2021 winner of The British Medical Journal’s prestigious UK Research Paper of the Year Award. This award recognises original UK research that has the potential to contribute significantly to improving health and healthcare. The paper, “Dexamethasone in Hospitalized Patients with Covid-19”, published in the New England Journal of Medicine, described the discovery in June 2020 of the world’s first effective, readily available treatment for COVID-19 – the inexpensive steroid, dexamethasone.

Tropical Medicine DPhil Students awarded NDM Prize

Every year, the Nuffield Department of Medicine awards NDM Prizes to our most outstanding students. This year, Mo yin and Rebecca Inglis (both at MORU) were highly commended in the category NDM Overall Prize, for conducting research with an outstanding impact. Will Schilling (MORU) received a prize as first year DPhil student, and Mohammad Ali (OCGHR) as second year DPhil student. Our warmest congratulations to you all!

New study alerts to the risk of poor quality medicines used to prevent and treat cardiovascular disease

There are important but neglected issues with substandard and falsified medicines and medical products used to prevent and treat cardiovascular diseases. From limited available data, MORU and IDDO scientists found about one fifth of medicines reported as sampled in the literature were substandard or falsified. This systematic review suggests that more and better quality data and data sharing are needed to better understand the global burden of this problem and inform interventions.

Systematic review identifies research gaps for Chagas disease

A new, large-scale systematic review published in PLOS Neglected Tropical Diseases has identified clear, significant research gaps in the diagnosis and treatment of Chagas disease. The paper also highlights significant differences in study design, diagnostic methods, duration of follow-up, and the timing of outcome assessment used by investigators even in the last decade.